Dr. Kline is a medical oncologist who specializes in the treatment of patients with Hodgkin and non-Hodgkin lymphoma, including stem cell transplantation and CAR T cell therapy. He has expertise in the development and use of immunotherapy, and his lab research is focused on overcoming immune evasion pathways activated in blood cancers and on improving the effectiveness of immune-based treatments for people with lymphoma.
University of Chicago
Chicago
- Hematology/Oncology
2007
University of Chicago
Chicago
- Internal medicine
2004
University of Chicago
Chicago
M.D. - Medicine
2001
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
PMID: 37851072
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
PMID: 33881502
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2).
PMID: 33361336
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
PMID: 33162369
The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
PMID: 31790142
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
PMID: 32018063
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
PMID: 31992847
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
PMID: 31725894
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019 07 10; 7(1):175.
PMID: 31291985